StockData
AC Immune SA logo

AC Immune SA (ACIU) stock

ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 13, 2026Score 3/30
$2.10−0.01 (-0.47%)

Close on Nov 18, 2026Market cap $213.66MP/E –Yield –

AC Immune operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

AC Immune's operating income for the twelve months ending Dec 31, 2022 was -CHF 70.85M. For fiscal 2025 it was -CHF 69.32M. The highest annual figure on record is CHF 44.54M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-CHF 69.32M–
FY2024Dec 31, 2024-CHF 52.38M–
FY2023Dec 31, 2023-CHF 53.62M–
FY2022Dec 31, 2022-CHF 70.85M–
FY2021Dec 31, 2021-CHF 79.01M–
FY2020Dec 31, 2020-CHF 61.26M-237.6%
FY2019Dec 31, 2019CHF 44.54M–
FY2018Dec 31, 2018-CHF 49.55M–
FY2017Dec 31, 2017-CHF 22.54M–
FY2016Dec 31, 2016-CHF 10.46M-156.1%
FY2015Dec 31, 2015CHF 18.62M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025-CHF 19.39M–
Q2 FY2024Jun 30, 2024-CHF 20.96M–
Q2 FY2023Jun 30, 2023-CHF 17.05M–
Q4 FY2022Dec 31, 2022-CHF 18.70M–
Q3 FY2022Sep 30, 2022-CHF 13.46M–
Q2 FY2022Jun 30, 2022-CHF 19.86M–
Q4 FY2021Dec 31, 2021-CHF 22.79M–
Q3 FY2021Sep 30, 2021-CHF 20.28M–
Q4 FY2018Dec 31, 2018-CHF 14.49M-554.4%
Q3 FY2018Sep 30, 2018-CHF 12.17M–
Q2 FY2018Jun 30, 2018-CHF 11.57M–
Q1 FY2018Mar 31, 2018-CHF 11.32M–
Q4 FY2017Dec 31, 2017CHF 3.19M–
Q3 FY2017Sep 30, 2017-CHF 9.64M–
Q2 FY2017Jun 30, 2017-CHF 8.25M–
Q1 FY2017Mar 31, 2017-CHF 7.83M–

More AC Immune figures

See a number that looks wrong?